OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2025-03-31-accounts

Company no. 04862177 Charity no. 1100518

Transform Drug Policy Foundation Report and Unaudited Financial Statements

31 March 2025

Transform Drug Policy Foundation

Reference and administrative details

For the year ended 31 March 2025

Company number 04862177
Charity number 1100518
Registered office and The Station
operational address Silver Street
Bristol
BS1 2AG

Trustees Trustees, who are also directors under company law, who served during the year and up to the date of this report were as follows:

Kenneth Aylmer Appointed 29 September 2025
Victoria Beere Appointed 2 September 2024
Courtney Brown Appointed 2 September 2024
Karl Burnett Appointed 2 September 2024
Nina Edmonds Resigned 1 December 2025
Katrina Ffrench Resigned 19 June 2024
Jonathan Gooch Appointed 13 January 2025
Nadia Islam Resigned 29 April 2024
Jay Jackson
Rebecca Kelly Appointed 2 September 2024
Jason Kew Resigned 29 September 2025
Rowan Miller Resigned 4 December 2024
Catherine Murphy Appointed 2 September 2024,
resigned 29 September 2025
Mark Robinson Resigned 13 January 2025
Victoria Unwin
Chief Executive Officer Jane Slater
Bankers Triodos Bank The Co-operative Bank
Deanery Road PO Box 250
Bristol Skelmersdale
BS1 5AS WN8 6WT
Independent Godfrey Wilson Limited
examiners Chartered accountants and statutory auditors
5th Floor Mariner House
62 Prince Street
Bristol
BS1 4QD

1

Transform Drug Policy Foundation

Report of the trustees

For the year ended 31 March 2025

The trustees present their report and accounts for the year ended 31 March 2025. Reference and administrative information set out on page 1 forms part of this report. The financial statements comply with current statutory requirements, the Memorandum and Articles of Association and the Statement of Recommended Practice - Accounting and Reporting by Charities (effective from January 2019).

Structure, governance and management

Governing document

Transform Drug Policy Foundation is a charitable company limited by guarantee (company number 04862177) and registered as a charity (charity number 1100518). The company was established under a Memorandum of Association and is governed by its Articles of Association. In the event of the company being wound up members are required to contribute an amount not exceeding £1. Its registered office is The Station, Silver Street, Bristol, BS1 2AG.

Risk management and assessment

The trustees are aware of their responsibilities to conduct a thorough risk assessment of the charity’s activities.

Currently risks are identified and controlled through a process of management overview of financial, managerial and strategic issues, coupled with frequent staff discussion and maintained in a risk register.

Appointment of trustees

The trustees who are directors for the purpose of company law and trustees for the purpose of charity law, who served for the year and up to the date of this report are set out on page 1. New trustees are appointed upon the recommendation of existing trustees and may involve external recruitment efforts using pro bono professional advice.

Trustee recruitment seeks to ensure a diverse range of skills, experience, and perspectives relevant to Transform’s strategic priorities.

Organisational structure

Day to day responsibility for the provision of services rests with the Chief Executive Officer Jane Slater.

Objectives and activities for the public benefit

The trustees have had regard to the guidance issued by the Charity Commission on public benefit.

The charity's activities during the year were the advancement of the education of the public and organisations in drug policy by research and dissemination of information, with a view to increasing the effectiveness of such policy and to preserve and safeguard the interests of the public. All our work is driven by the need to improve policy so that it better protects people according to reputable evidence.

2

Transform Drug Policy Foundation

Report of the trustees

For the year ended 31 March 2025

Chair’s Report:

Achievements and performance

Like many people, it is a personal story that shaped my motivations as a drug policy reform advocate. As the mother of a daughter who died from a ketamine overdose, aged just 21, it is my belief in the ability of a small organisation to deliver meaningful change, that can help prevent the tragedies that my family experienced. It is this that led me to my role as a Transform trustee and, since October 2023, Transform Chair.

The impact that an organisation of Transform’s size can have still has the power to impress me. The scope of the Transform team’s work is nothing short of remarkable. From helping to deliver life saving reforms in local harm reduction provision in the UK, to working with governments around the world and operating as UN consultants. As we look forward to 2026 and beyond I want to celebrate some of these achievements from the past year.

Transform’s ‘Anyone’s Child’ campaign was how I originally came to the organisation. It supports families impacted by the war on drugs, whether through bereavement, incarceration or other trauma, to tell their stories and call for reform. Anyone’s Child has continued to be a powerful influence on the national conversation; in mainstream media, and in a range of local and national policy forums. Our ‘Take Drugs Seriously’ public events continue to bring together local communities, police, policy makers, and health professionals for grown-up conversations about drug policy and reform; what’s working, what’s not, and what could be done differently and better. We have witnessed these events catalyse localities to consider and implement alternative approaches to drug policy, enabling them to push forward reforms despite the confines of UK law. At the same time the families’ stories, often cited in Parliament, are supporting the national debate on reforming the laws themselves.

2024/2025 saw two major developments in the UK; the opening of the UK’s first overdose prevention centre in Glasgow; and the launch of the first Home Office licensed drug-checking services in Bristol. These major developments come as a result of years of advocacy work by Transform and colleagues and mark a decisive and positive shift to more pragmatic harm-reduction led response to the UK’s drug crisis.

This year we launched our new #LegaliseUKCannabis campaign to progress the conversation and momentum for reform here in the UK. Our new briefing - High Returns: The Economic Benefits of UK cannabis regulation - was launched in Parliament in 2025. The campaign shows how Transform remains a key driver behind cannabis legalisation and regulation, and has allowed us to bring our global expertise to bear in the UK. We have worked as consultant advisers with the governments in Malta, Luxembourg, the Netherlands, Canada, Uruguay and Czechia on cannabis reforms. With demand growing for our insights, our cannabis regulation guide - How to Regulate Cannabis: A Practical Guide , now in its third edition, has been translated into Spanish, Portuguese, German and Czech.

Internationally, we have also been closely involved in critical drug policy discussions. Our work has directly supported the significant evolution of institutional positions, with Amnesty International (the world’s largest Human Rights organisation) and the UN Office of the High Commissioner for Human Rights, both adopting positions advocating for regulation of all drugs. We have also led the drafting of

3

Transform Drug Policy Foundation

Report of the trustees

For the year ended 31 March 2025

a major new report for the United Nations Development Program- the first UN report to interrogate the impacts of regulation through a development lens.

We give our thanks to Transform’s funders and donors who continue to support our work in these uncertain times, along with our activists, volunteers, and champions in different communities and professional domains. We remain committed to our vision of a world where drug policy protects people from harm. It has been another momentous year for drug policy reform as it continues to accelerate across the world - and Transform has been at the heart of much of this progress.

Financial review

During the year we successfully maintained our funding base via individual donations and continued funding from trusts and foundations. The overall performance for the year is positive, with a net surplus of £10,296, compared to the prior year’s deficit of £151,324. This is in part due to a modest increase in income, rising from £232,946 in 2024 to £271,866 in 2025, and also due to a substantial reduction in costs, with total expenditure for the year of £261,570 (2024: £384,270). The reduction in expenditure is primarily due to a reduction in staff costs and corresponding average headcount (£187,646, 6 people, vs 2024: £281,402, 8 people), and moving to a single CEO leadership structure.

At the year end, the total reserves of the charity were £242,772 (2024: £232,476), comprising restricted funds of £58,363 (2024: £32,099), and unrestricted general funds of £184,409 (2024: £115,477). The majority of the charity’s assets are held as cash which at 31 March 2025 was £254,677 (2024: £242,740).

Volunteers

During the year volunteers donated their services to the charity. The trustees estimate that these services in kind had a value of the order of £6,300.

Funders

Funds are received via grant-making trusts and from donations made by a wide range of individuals in the form of monthly direct debits, one-off payments, gifts in kind and larger donations made annually or several times a year. Donations are also collected at special events.

Reserves policy

The trustees have examined the charity’s requirements for reserves in light of the main risks to the organisation. It has established a policy whereby a designated fund should be established to meet: the working capital requirements of the charity for a period of 3 months in case future grants are not forthcoming; statutory payments liabilities for all staff; other liabilities. At 31 March 2025, this is calculated as being £56,300. An amount of £56,300 has been maintained from unrestricted funds for this purpose, held in cash at the bank. Full details are set out in our Reserves and Investment Policy.

Statement of responsibilities of the trustees

The trustees (who are also directors of the charity for the purposes of company law) are responsible for preparing the trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102: The Financial

4

Transform Drug Policy Foundation

Report of the trustees

For the year ended 31 March 2025

Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year, which give a true and fair view of the state of affairs of the charity and of the income and expenditure of the charity for that period. In preparing those financial statements the trustees are required to:

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charity and which enable them to ensure that the financial statements comply with the Companies Act 2006. The trustees are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees confirm that to the best of their knowledge there is no information relevant to the examination of which the independent examiners are unaware. The trustees also confirm that they have taken all necessary steps to ensure that they themselves are aware of all relevant examination information and that this information has been communicated to the independent examiners.

Members of the charity guarantee to contribute an amount not exceeding £1 to the assets of the charity in the event of winding up. The trustees are members of the charity but this entitles them only to voting rights. The trustees have no beneficial interest in the charity.

Independent examiners

Godfrey Wilson Limited were re-appointed as independent examiners to the charitable company during the year and have expressed their willingness to continue in that capacity.

Approved by the trustees on 1 December 2025 and signed on their behalf by

Victoria Unwin - Chair

5

Independent examiner's report

To the trustees of

Transform Drug Policy Foundation

I report to the trustees on my examination of the accounts of Transform Drug Policy Foundation (the charitable company) for the year ended 31 March 2025, which are set out on pages 7 to 18.

Responsibilities and basis of report

As the trustees of the charitable company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 (‘the 2006 Act’).

Having satisfied myself that the accounts of the charitable company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the charitable company's accounts as carried out under section 145 of the Charities Act 2011 (‘the 2011 Act’). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.

Independent examiner’s statement

Since the charitable company’s gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants in England and Wales (ICAEW), which is one of the listed bodies.

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Dougal Howard

Date: 1 December 2025 Dougal Howard ACA Member of the ICAEW For and on behalf of: Godfrey Wilson Limited Chartered accountants and statutory auditors 5th Floor Mariner House 62 Prince Street Bristol BS1 4QD

6

Transform Drug Policy Foundation

Statement of financial activities (incorporating an income and expenditure account)

For the year ended 31 March 2025

Restricted
Note
£
Income from:
Donations
3
40,000
Charitable activities
4
-
Investments
-
Total income
40,000
Expenditure on:
Raising funds
-
Charitable activities
13,736
Total expenditure
6
13,736
Net income / (expenditure)
and net movement in funds
7
26,264
Reconciliation of funds:
Total funds brought forward
32,099
Total funds carried forward
58,363		 Unrestricted
£
213,282
15,017
3,567
231,866
2,441
245,393
247,834
(15,968)
200,377
184,409		 2025
Total
£
253,282
15,017
3,567
271,866
2,441
259,129
261,570
10,296
232,476
242,772		 2024
Total
£
215,735
14,201
3,010
232,946
11,496
372,774
384,270
(151,324)
383,800
232,476

All of the above results are derived from continuing activities. There were no other recognised gains or losses other than those stated above. Movements in funds are disclosed in note 12 to the accounts.

7

Transform Drug Policy Foundation

Balance sheet

As at 31 March 2025

Note
Current assets
Debtors
10
Cash at bank and in hand
Liabilities
Creditors: amounts falling due within 1 year
11
Net current assets
Net assets
12
Funds
13
Restricted funds
Unrestricted funds
Designated funds
General funds
Total charity funds		 £
642
254,677		 2025
£
255,319
(12,547)
242,772
242,772
58,363
-
184,409
242,772		 2024
£
4,160
242,740
246,900
(14,424)
232,476
232,476
32,099
84,900
115,477
232,476

The directors are satisfied that the company is entitled to exemption from the provisions of the Companies Act 2006 (the Act) relating to the audit of the financial statements for the year by virtue of section 477, and that no member or members have requested an audit pursuant to section 476 of the Act.

The directors acknowledge their responsibilities for:

These accounts have been prepared in accordance with the special provisions applicable to companies subject to the small companies' regime.

Approved by the trustees on 1 December 2025 and signed on their behalf by

Victoria Unwin - Chair

8

Transform Drug Policy Foundation

Notes to the financial statements

For the year ended 31 March 2025

1. Accounting policies

a) General information and basis of preparation

Transform Drug Policy Foundation is a charitable company limited by guarantee registered in England and Wales. The registered office address is The Station, Silver Street, Bristol, BS1 2AG.

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities in preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

Transform Drug Policy Foundation meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note.

b) Going concern basis of accounting

The accounts have been prepared on the assumption that the charity is able to continue as a going concern, which the trustees consider appropriate having regard to the current level of unrestricted reserves. There are no material uncertainties about the charity's ability to continue as a going concern.

c) Income

Income is recognised when the charity has entitlement to the funds, any performance conditions attached to the item of income have been met, it is probable that the income will be received and the amount can be measured reliably.

Income from the government and other grants, whether 'capital' grants or 'revenue' grants, is recognised when the charity has entitlement to the funds, any performance conditions attached to the grants have been met, it is probable that the income will be received and the amount can be measured reliably and is not deferred.

d) Donated services and facilities

Donated professional services and donated facilities are recognised as income when the charity has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use by the charity of the item, is probable and the economic benefit can be measured reliably. In accordance with the Charities SORP (FRS 102), general volunteer time is not recognised.

On receipt, donated professional services and donated facilities are recognised on the basis of the value of the gift to the charity which is the amount the charity would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

e) Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity: this is normally upon notification of the interest paid or payable by the bank.

9

Transform Drug Policy Foundation

Notes to the financial statements

For the year ended 31 March 2025

1. Accounting policies (continued)

f) Funds accounting

g) Expenditure and irrecoverable VAT

Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably.

Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred.

h) Allocation of support and governance costs

Support and governance costs are those functions that assist the work of the charity but do not directly undertake charitable activities. These costs have been allocated in full to expenditure on charitable activities which is deemed to be reflective of the activities of the charity in this period.

i) Debtors

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

j) Cash at bank and in hand

Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

k) Creditors

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

l) Financial instruments

The charitable company only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently recognised at amortised cost using the effective interest method.

m) Pension costs

The company operates a defined contribution pension scheme for its employees. There are no further liabilities other than that already recognised in the SOFA.

n) Foreign currency transactions

Transactions in foreign currencies are translated at rates prevailing at the date of the transaction. Balances denominated in foreign currencies are translated at the rate of exchange prevailing at the year end.

10

Transform Drug Policy Foundation

Notes to the financial statements

For the year ended 31 March 2025

1. Accounting policies (continued)

o) Accounting estimates and key judgements

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

There were no sources of estimation uncertainty that have a significant effect on the amounts recognised in the financial statements during the year.

2. Prior period comparatives: statement of financial activities

Income from:
Donations and legacies
Charitable activities
Investments
Total income
Expenditure on:
Raising funds
Charitable activities
Total expenditure
Net income / (expenditure)
and net movement in funds		 Restricted
£
£
104,531
111,204
-
14,201
-
3,010
104,531
128,415
-
11,496
123,145
249,629
123,145
261,125
(18,614)
(132,710)
Unrestricted		 2024
Total
£
215,735
14,201
3,010
232,946
11,496
372,774
384,270
(151,324)

11

Transform Drug Policy Foundation

Notes to the financial statements

For the year ended 31 March 2025

3. Income from donations

Grants
Glass House Trust
The Open Society Foundation
Garfield Weston
National Lottery
Donations
The Linnet Trust
Gifts in kind
Other donations
Total from donations*		 2025
Restricted
Total
£
£
£
-
17,500
17,500
-
53,006
53,006
20,000
-
20,000
20,000
-
20,000
-
10,000
10,000
-
26,000
26,000
-
106,776
106,776
40,000
213,282
253,282
Unrestricted

*Gifts in kind represents pro bono accounting and fundraising support, as well as the charity's website and digital productions.

Prior period comparative

Grants
AB Charitable Trust
Brigstow Institute
Glass House Trust
John Ellerman Foundation
Linnet Trust
Orr Mackintosh Foundation
Tudor Trust
University of Bristol
Donations
Gifts in kind
Other donations
Total from donations*		 2024
Restricted
Total
£
£
£
-
20,000
20,000
13,006
-
13,006
-
15,000
15,000
40,000
-
40,000
-
10,000
10,000
-
30,000
30,000
50,000
-
50,000
1,525
-
1,525
-
8,000
8,000
-
28,204
28,204
104,531
111,204
215,735
Unrestricted

12

Transform Drug Policy Foundation

Notes to the financial statements

For the year ended 31 March 2025

4. Income from charitable activities

Income from charitable activities
Consultancy
Event income
Sales of merchandise
Total income from charitable activities		 2025
Total
£
14,322
518
177
15,017		 2024
Total
£
13,781
85
335
14,201

All income from charitable activities in the current and prior period was unrestricted.

5. Government grants

The charitable company receives government grants, defined as funding from the National Lottery to fund charitable activities. The total value of such grants in the period ending 31 March 2025 was £20,000 (2024: £nil). There are no unfulfilled conditions or contingencies attaching to these grants in 2025/26.

6. Total expenditure

Staff costs (note 8)
Training and recruitment
Postage and stationery
Printing and design
Subscriptions, licences and charges
Travel and subsistence
Event costs
Digital productions
Equipment and software
Legal and professional
Office costs
Rent, rates and utilities
Insurance
Accountancy
Bank charges
Sub-total
Allocation of support and
governance costs
Total expenditure		 Raising
funds
£
2,441
-
-
-
-
-
-
-
-
-
-
-
-
-
-
2,441
-
2,441		 Charitable
activities
£
182,172
-
-
2,602
-
415
20,080
6,080
-
20,150
-
-
-
-
-
231,499
27,630
259,129		 £
3,033
-
510
-
2,743
-
-
-
3,904
-
817
6,249
855
9,226
293
27,630
(27,630)
-
Support and
governance
costs		 2025 Total
£
187,646
-
510
2,602
2,743
415
20,080
6,080
3,904
20,150
817
6,249
855
9,226
293
261,570
-
261,570

Total governance costs were £2,250 (2024: £2,160).

13

Transform Drug Policy Foundation

Notes to the financial statements

For the year ended 31 March 2025

6.
Total expenditure (continued)
Prior period comparative
Staff costs (note 8)
Training and recruitment
Postage and stationery
Printing and design
Subscriptions, licences and charges
Travel and subsistence
Event costs
Digital productions
Equipment and software
Legal and professional
Office costs
Rent, rates and utilities
Insurance
Accountancy
Bank charges
Sub-total
Allocation of support and governance
costs
Total expenditure		 Raising
funds
£
11,496
-
-
-
-
-
-
-
-
-
-
-
-
-
-
11,496
-
11,496		 Charitable
activities
£
250,313
1,195
-
2,208
-
2,955
32,142
10,368
-
18,099
-
-
-
-
-
317,280
55,494
372,774		 2024 Total
£
£
19,593
281,402
-
1,195
1,441
1,441
-
2,208
3,590
3,590
-
2,955
-
32,142
-
10,368
3,813
3,813
-
18,099
4,561
4,561
8,004
8,004
1,635
1,635
12,596
12,596
261
261
55,494
384,270
(55,494)
-
-
384,270
Support and
governance
costs

14

Transform Drug Policy Foundation

Notes to the financial statements

For the year ended 31 March 2025

7. Net movement in funds

This is stated after charging:

Trustees' remuneration
Trustees' reimbursed expenses
Independent examiner's remuneration:
Independent examination (excluding VAT)		 2025
£
Nil
406
1,875		 2024
£
Nil
46
1,800

In common with other charities of our size and nature we use our independent examiners to assist with the preparation of the financial statements.

8. Staff costs and numbers

Staff costs were as follows:

Salaries and wages
Social security costs
Pension costs		 2025
£
163,830
16,089
7,727
187,646		 2024
£
249,621
19,800
11,981
281,402

No employee earned more than £60,000 during the current or prior year.

The key management personnel of the charitable company comprise the Trustees, the outgoing Co-CEO, and the current CEO (2024: the Trustees and two Co-CEOs). The total employee benefits of the key management personnel were £68,024 (2024: £68,931).

Average head count 2025
No.
6		 2024
No.
8

9. Taxation

The charity is exempt from corporation tax as all its income is charitable and is applied for charitable purposes.

15

Transform Drug Policy Foundation

Notes to the financial statements

For the year ended 31 March 2025

10. Debtors

Trade debtors
Prepayments
Other debtors
11. Creditors: amounts due within 1 year
Trade creditors
Accruals
Other taxation and social security
Other creditors		 2025
£
387
255
-
642
2025
£
3,371
5,224
2,411
1,541
12,547		 2024
£
-
1,089
3,071
4,160
2024
£
730
7,315
4,203
2,176
14,424

12. Analysis of net assets between funds

Current assets
Current liabilities
Net assets at 31 March 2025
Prior year comparative
Current assets
Current liabilities
Net assets at 31 March 2024		 Restricted
funds
£
58,363
-
58,363
Restricted
funds
£
32,099
-
32,099		 Designated
funds
£
-
-
-
Designated
funds
£
84,900
-
84,900		 General
funds
£
196,956
(12,547)
184,409
General
funds
£
129,901
(14,424)
115,477		 Total
funds
£
255,319
(12,547)
242,772
Total funds
£
246,900
(14,424)
232,476

16

Transform Drug Policy Foundation

Notes to the financial statements

For the year ended 31 March 2025

13. Movements in funds

Restricted funds
Anyone's Child
Garfield Weston
The National Lottery
Total restricted funds
Unrestricted funds
Designated funds:
Reserves fund
Total designated funds
General funds
Total unrestricted funds
Total funds		 At 1 April
2024
£
32,099
-
-
32,099
84,900
84,900
115,477
200,377
232,476		 Income
£
£
-
(3,439)
20,000
(4,383)
20,000
(5,914)
40,000
(13,736)
-
-
-
-
231,866
(247,834)
231,866
(247,834)
271,866
(261,570)
Expenditure		 Transfers
between
funds
£
-
-
-
-
(84,900)
(84,900)
84,900
-
-		 At 31
March
2025
£
28,660
15,617
14,086
58,363
-
-
184,409
184,409
242,772

Purposes of restricted funds Anyone's Child The Anyone's Child project, funded by the Tudor Trust and the John Ellerman Foundation, aims to enable families impacted by current drug policy to speak out.

Garfield Weston

Funding received from Garfield Weston to support the Anyone's Child project.

The National Lottery

Funding received from the National Lottery to support the Anyone's Child project.

Purposes of designated funds Reserves fund

The transfer out of the reserves designated fund represents the movement of this balance back to within the general funds of the charity.

17

Transform Drug Policy Foundation

Notes to the financial statements

For the year ended 31 March 2025

13. Movements in funds (continued)

Prior year comparative
Restricted funds
Anyone's Child
Trust for London
University of Bristol
Brigstow Institute
Total restricted funds
Unrestricted funds
Designated funds:
Open Society Foundation
Esmée Fairbairn Foundation
Reserves fund
Trustee donation
Total designated funds
General funds
Total unrestricted funds
Total funds		 At 1 April
2023
£
35,311
15,402
-
-
50,713
152,312
20,004
126,000
22,986
321,302
11,785
333,087
383,800		 Income
£
£
90,000
(93,212)
-
(15,402)
1,525
(1,525)
13,006
(13,006)
104,531
(123,145)
-
(152,312)
-
(20,004)
-
-
-
(22,986)
-
(195,302)
128,415
(65,823)
128,415
(261,125)
232,946
(384,270)
Expenditure		 Transfers
between
funds
£
£
-
32,099
-
-
-
-
-
-
-
32,099
-
-
-
-
(41,100)
84,900
-
-
(41,100)
84,900
41,100
115,477
-
200,377
-
232,476
At 31 March
2024		 Transfers
between
funds
£
£
-
32,099
-
-
-
-
-
-
-
32,099
-
-
-
-
(41,100)
84,900
-
-
(41,100)
84,900
41,100
115,477
-
200,377
-
232,476
At 31 March
2024
32,099
-
-
84,900
-
84,900
115,477
200,377
232,476

14. Related party transactions

There were no related party transactions during the current or prior year.

18